# Company Presentation full year 2020











### Sol Group in a glance

- Founded in 1927, is an Italian multinational company, present in 29 countries with more than 4.600 employees
- Two core, separated but integrated and synergic business areas: Technical Gas sector (production, applied research and marketing of pure, medical and industrial gases) and Home-Care service sector (supply of medical products and medical assistance services as well as equipment for home care therapy)
- Two recent businesses: Hydro Energy and Biotechnology



# Sol Group in a glance

- . Solid performance in 2020:
  - 974 millions € of sales (+7,7%)
  - 56,9% of international revenues in 2020 (vs 23,7 % in 2000)
  - 6.5% of compound average growth rate during the last 10 years
  - 26.2% of EBITDA marging in 2020
  - 0,378 of Debt/Equity ratio; 0,98 of Debt/EBITDA ratio
  - Dividend policy: 30% average dividend pay out ratio over the last 10 years




SOL is **listed** at the Stock Exchange of Milan since July 1998





# SOL has been founded in Italy (at Monza) on 1927 from the 2 **families** Annoni and Fumagalli: 90 years of history – three generations of entrepreneurs














# The major Italian Chemical Companies (2020)

(million Euro)		Worldsales	Italian sales	(million Euro)	World sales	Italian sales
1.	Versalis	3.381	2.545	21. Gruppo Desa	326	324
2.	Gruppo Mapei	2.772	837	22. Fluorsid Group	325	183
3.	Gruppo Bracco	1.199	656	23. Novamont	286	286
4.	Radici Group	1.019	621	24. FACI Group	237	94
5.	Gruppo SOL_	974	420	25. Reagens	235	102
6.	P & R Group	864	792	26. Indena/Gr. IdB Holding	217	177
7.	COIM Group	780	399	27. Gruppo Metlac	216	216
8.	Gruppo SIAD	692	507	28. 3V Partecipaz. Industriali	208	140
9.	Polynt Group	671	488	29. Alfa Parf Group	204	33
10	. Gruppo Sapio	629	532	30. Sabo	173	173
11	. Gruppo Intercos	604	355	31. Sadepan Chimica	170	122
12	. Gruppo Sodalis	585	350	32. Mirato Group	167	167
13	. Gruppo Colorobbia	526	200	33. Gruppo Silvateam	156	111
14	. Italmatch Chemicals	518	141	34. Davines	153	153
15	. FIS	516	500	35. Gruppo Coswell	152	152
16	. Gruppo Zobele	509	78	36. Gr. Durante/TLD Holding	152	150
17	′. Gruppo Sipcam-Oxon	461	279	37. Istituto Ganassini	152	85
18	3. Esseco Group	439	241	38. Gruppo Bozzetto	152	56
19	. Gruppo Aquafil	437	170	39. AGF88 Holding	135	135
20	). Gruppo Lamberti	421	206	40. Paglieri	135	135



Note: companies with majority of Italian capital; values refer to chemical sales (no pharmaceutical sales)


# Sol Group - 30 years Turnover (1990-2020)








# Sol Group – Consolidated sales (M€)








# Sol Group


EBITDA (M€)



2019

2020







2018

**The Technical Gases Business** 





#### The Technical Gases Business

SOL Group operates in the technical gases business throughout the brand SOL

#### **Production and distribution of Gases**

A complete range of industrial gas (both atmospheric and non-atmospheric): medicinal, pure and special gases

- Oxygen
- Nitrogen
- Argon
- Hydrogen Carbon dioxide
- Acetylene
- Nitrous oxide
- Gas mixtures
- Ultra high purity gases
- Medical gases
- ◆ Gaseous helium
- Liquid helium
- Refrigerating gases
- ◆ Electronics gases
- Ammonia
- Combustible gases
- ◆ Sulfur oxide SO2
- Nitric oxide NO

#### Supply of plants, equipment, services and consultancy

Research, design, and construction of:

- Industrial gas production facilities
- Plant and equipment for gas utilization
- **Services and consultancy**

- Equipment for medical applications
- ◆ Equipment for cryogenic applications ◆ On-site plants
- Deep freezing tunnels
- Oxygen burners
- Ozonisers

- ◆ Medical air plants
- Welding machines and equipment





# More than 100 technologies for the industrial sector






#### **Technical Gases Business**

Technical gases business (M€)	FY2020	FY2019	YoY
Sales	470	443	+ 6.3%
EBITDA	95	77	+ 23.8%
EBITDA %	20.2%	17.3%	
Investments	52	53	- 1.0%

- In 2020 the division invested over the 11% of its revenues.
- . 3.8% sales CAGR over the last 10 ys.







#### **Technical Gases business**

#### **Market characteristics**

- Resilient and growing market
- Margin protected thanks to high entry barriers
- Limited economic cycle demand dependence of each sales area
  - Broad variety and diversification of end-markets and applications
- Medium/long term contracts
- Local presence as a key factor

#### SOL

- . High diversification of sales area:
  - . More than 50,000 clients served;
  - More than 90 different applications for technical gases
- Long term contracts with customers:
  - . Gas pipeline: up to 15 years;
  - Compressed gases: up to 5 years;
  - Cryogenic liquid gases: up to 3 years
- Strong local presence:
  - 26 countries, 38 sources and primary transformation plants, 49 secondary transformation plants.





Resilience + Growth + Demand stability + Low risk level

#### **Primary Sources & Production Sites** AIR SEPARATION / LIQUEFACTION - OXYGEN, NITROGEN, ARGON **HYDROGEN - H2 CARBON DIOXIDE - CO2** ACETYLENE - C2H2 **NITROUS OXIDE - N2O** India **NITRIC OXIDE - NO SULFUR DIOXIDE - S20** . 40 primary production sites: units that produce gases from row materials (electric atmospheric energy, natural gas, calcium carbide and ammonium nitrate). . Max reach-in area is 400 km. **SOL**GROUP Morocco




















PLANT	SOURCE	
Falconara	Chemical plant	
Novara	Chemical plant	
Devnya	Chemical plant	
Bitola	Well	
Petrovo	Well	
BurgBrohl	Well	
Florina	Well	
Ihtiman	Ethanol production	
Zeitz	Ethanol production	
Biowanze	Ethanol production	







# SOL Group CO2 plants
















**The Home Care Business** 





#### Home Care - VIVISOL branches

wivisol is n° 2
market leader in
Europe, operating
in 14 European
Countries, as well
as in Brazil and
Turkey, through its
network of over 70
offices and service
points





### Home Care - VIVISOL branches



**VIVISOL Nederland – Tilburg** 



**VIVISOL Belgium - Lessines** 



**VIVISOL Austria – Vienna** 







**Arnstadt** 



#### The Home Care Business

A complete range of services and technologies, specifically designed to take care of more than 500.000 patients affected by different chronic diseases

















**Oxygen Therapy** 

**Ventilation Therapy** 



**Sleep Related Disorders** 

















**Nutrition & Infusion** 

**Advanced Home Care** 

**Telemedicine** 

**Palliative Care** 




#### **Home Care Business**

Hone Care business (M€)	FY2020	FY2019	YoY
Sales	537	493	+ 8,9%
EBITDA	161	135	+ 19,4%
EBITDA %	29.9%	27.3%	
Investments	60	50	+ 20%

- VIVISOL was able to grow 8.9% in 2020, with an EBITDA margin higher than 29%.
- The Group is continuing to invest significantly in this business.





**SOL Group 2020 Total revenues** 



#### **Home Care Business**



#### **Key growth drivers:**

- Aging population demographics
- Restructuring of Health Care Systems through de-hospitalization and home care
- Developments in portable medical technologies
- Better quality of life for Patients at home
- Increasing of respiratory and chronic pathologies









# Sol Group – SALES (Home Care vs Technical Gases – tot Health Care)

Achieved 2010-2020







The Biotechnology Business






## The Biotechnology Business

SOL Group is active in supplying biotechnological equipment and services to hospitals, clinics and laboratories (cryobanks, cellfactories, cryomanagement, cryotransportation)

With BIOTECHSOL and CRYOLAB is active in the area of tissue and stem cells banking and biological materials transportation.

With **DIATHEVA** is active in drug discovery and drug delivery (recombinant monoclonal antibodies), molecular diagnostic, **GMP** production of recombinant proteins

With PERSONAL GENOMICS is active in genetic analysis service and genetic testing research and development.
















The Hydro-Energy Business





## The Hydro-Energy Business

- Leveraging on its core business development in the Eastern Europe, SOL entered into the Hydro-Energy sector.
- The industrial gas sector, is one of the most energy intensive one. This characteristic supported the Group decision to invest in the Hydro-Energy sector in order to enjoy synergies with its Industrial Gases Business.






Currently the company owns and operates 6 hydro-electric power plants in Slovenia (about 50 Million KWh/year), 2 plants in Albania (about 25 Million KWh/year); 4 plants in Macedonia (about 35 Million KWh/year); 4 plants in Bosnia (about 6 Million KWh/year).



# 2020

# A Capital of Human Resources continuously growing



2020

# 29 NATIONALITIES

A huge potential and a great variety of cultures












### Sol Group - consolidated results (2010 – 2020)

**SOL**GROUP




## Sol Group – internazionalization







### **International Expansion**









# 62 JV & ACQUISITION (2000-2021)

Company		Year of acquisition	Division	
FRANCE OXYGENE	France	2000	Home Care	
HGT	Greece	2000	Technical Gases	
TGT	Bosnia	2001	Technical Gases	
ZEUS	Greece	2001	Technical Gases	
BEHRINGER	Italy	2002	Technical Gases	
ENERGETIKA	Slovenia	2002	Technical Gases	
HOSPITAL SERVICE	Italy	2002	Home Care	
TGP	Bosnia	2002	Technical Gases	
ELOMED	Germany	2003	Home Care	
IL POINT	Italy	2004	Home Care	
OXYMED	Germany	2004	Home Care	
MEDIZIN SERVICE	Germany	2006	Home Care	
MEDIZIN TECHNIK	Germany	2006	Home Care	
JULIA GAS	Italy	2007	Technical Gases	
RESMED	Austria	2008	Home Care	
BOESCH	Germany	2009	Home Care	
JLV	Spain	2009	Home Care	
DOLBY	UK - Scotland	2010	Home Care	
FRODITHYA	Greece	2010	Home Care	
MEDES	Italy	2010	Technical Gases	
OSSIGEN GAS	Italy	2010	Technical Gases	
SICGILSOL	India	2010	Technical Gases	
GTH	Romania	2011	Technical Gases	
HYDROENERGY	Albania	2011	Technical Gases	
DIATHEVA	Italy	2012	Biotech	
MEDICAL SYSTEM	Italy	2012	Technical Gases	
VIVISOL TK	Turkey	2012	Home Care	
СТВ	Germany	2014	Technical Gases	
MBAR	France	2014	Home Care	
SKS	Germany	2014	Technical Gases	
TESI	Italy	2014	Technical Gases	

Company		Year of acquisition	Division	
VIVISOL ADRIA	Slovenia	2014	Home Care	
CRYOLAB	Italia	2015	Biotech	
FLOSIT	Morocco	2015	Technical Gases	
INSPIRAR	Brazil	2015	Home Care	
PIELMEIER	Germany	2015	Home Care	
SEVA	India	2015	Technical Gases	
SONOCARE	Potugal	2015	Home Care	
IRISH OXYGEN COMPANY	Ireland	2016	Technical Gases	
KOMPASS	Germany	2016	Home Care	
MEL	Bosnia	2016	Technical Gases	
DIRECT MEDICAL	Ireland	2017	Home Care	
GEBZE GAZ	Turkey	2017	Technical Gases	
PERSONAL GENOMICS	Italy	2017	Biotech	
RESPITEK	Turkey	2017	Home Care	
REVI	Italy	2017	Technical Gases	
SITEX	Switzerland	2017	Home Care	
STERIMED	Italy	2017	Technical Gases	
CRYOS	Italy	2018	Technical Gases	
FISIOMED	Italy	2018	Home care	
MEDSEVEN	Poland	2018	Home care	
PALLMED	Poland	2018	Home care	
MEDTEK	Germany	2018	Home care	
Wanninger	Germany	2019	Home care	
PPAR	Brazil	2019	Home care	
Unit Care	Brazil	2019	Home care	
DN GLOBAL	Brazil	2019	Home care	
GLOBAR CARE	Brazil	2019	Home care	
SPITEX PERSPECTA	Switzerland	2019	Home Care	
SOL India	India	2021	Technical Gases	
TAE Hellas	Greece	2021	Technical Gases	
VIVICARE Hellas	Greece	2021	Home Care	



### Capital Expenditures & Acquisition (2010-2020)

### 10 years of Capex & M&A on sales 2010-2020



### **High annual investments**

- The Group every year invest about 16% of its revenues;
- The Sol business require a high level of investments for long term growth options;
- In 2020 almost the 63% of the Group investments in CAPEX (without M&A) was made outside Italy.





# 2020

# A policy of strong investments also in the most difficult context

Capex
Technical Investments



### **Record investments in 2020**


A series of <u>structural investments</u> for the <u>growth</u> of the Group in the years to come




### 10 years net profit and dividend growth



#### NET PROFIT






**DPS - Dividend Yield** 

**10Y AVERAGE PAY-OUT RATIO 30%** 





### Shareholding information and market price



Source: Borsa Italiana

### **Outstanding Shares**

- . 90.700.000 ordinary shares
- . par value: 0,52

### **Shareholding Structure**

- Fumagalli and Annoni families 60%
- . Main Institutional Investors:
  - . Tweedy Brown
  - . Azvalor





# **SOL Group - Consolidated Income Statement**

(thousands Euro)			
	31.12.20	31.12.19	2020/ 2019
Net turnover	973,833	904,313	+ 7,7%
Total revenues	996,196 102.3%	926,858 102.5%	+ 7,5%
Added value	468,401	416,422	+ 12,5%
EBITDA	48.1% 255,392	46.0% 211,307	+ 20,9%
EBIT	26.2% 139,987	23.4% 88,660	+ 57,9%
	14.4%	9.8%	31,311



# SOL Group - Consolidated Income Statement

Thousands Euro)			I	
	31.12.	20	31.12.	19
		%		%
Net turnover	973,833	100.0	904,313	100.0
Other revenues	9,875	1.0	8,883	1.0
Internal work capitalized	12,488	1.3	13,662	1.5
Total revenues	996,196	102.3	926,858	102.5
Raw materials	240,540	24.7	212,870	23.5
Services	277,282	28.5	272,233	30.1
Stocks	(14,459)	(1.5)	1,752	0.2
Other costs	24,432	2.5	23,580	2.6
Total costs	527,794	54.2	510,436	56.4
Added value	468,401	48.1	416,422	46.0
Labour costs	213,009	21.9	205,115	22.7
EBITDA	255,392	26.2	211,307	23.4



# SOL Group - Consolidated Income Statement

ousands Euro)				
	31.12.2	20	31.12.1	L9
		%		%
EBITDA	255,392	26.2	211,307	23.4
Depreciation & Amortization	110,986	11.4	105,472	11.7
Other provisions	4,419	0.5	7,066	0.8
Operating income recurring	139,987	14.4	98,769	10.9
Non recurring (Income)/Charges	-	-	10,109	1.1
EBIT	139,987	14.4	88,660	9.8
Net financial	(9,810)	(1.0)	(8,459)	(0.9)
PBT	130,177	13.4	80,201	8.9
Taxes	21,943	2.3	27,784	3.1
Net profit from ongoing operations	108,234	11.1	52,417	5.8
Minorities	(5,187)	(0.5)	(3,079)	(0.3)
NET PROFIT	103,047	10.6	49,338	5.5
EPS	1.136		0.544	



# SOL Group - Consolidated Balance Sheet

(Thousands Euro)			<b>.</b>		
	31.12.20	31.12.19		31.12.20	31.12.19
Assets			Liabilities		
Net fixed assets	554.6	534.1	Shareholder's equity	635.7	560.6
Other fixed assets	196.3	184.7	Minorities	27.2	19.4
Cash and liquid assets	269.2	169.3	Financial debts	446.6	400.8
Inventory	63.3	49.5	Other non current liabilities	23.9	21.9
Net receivables	297.9	280.1	Payables	122.2	108.5
Other current assets	32.9	36.7	Other current liabilities	158.8	143.3
Total assets	1,414.3	1,254.4	Total liabilities	1,414.3	1,254.4



# **SOL Group - Net Financial Position**

(Thousands Euro)

	31.12.20	31.12.19
Cash and cash at bank	269,181	169,326
Securities	6,300	4,147
Loans - current portion	(63,612)	(55,327)
Leases - current portion	(15,319)	(14,338)
Due to shareholders	(1,857)	(2,415)
Other financial receivables - current portion	1,166	3,920
Other financial liabilities - current portion	(2,589)	(2,034)
Short term liquidity	193,269	103,279
Investments securities	1,156	1,055
Loans - long term portion	(405,463)	(361,937)
Leases - long term portion	(36,488)	(34,686)
Due to shareholders	0	(1,107)
Other financial receivables - long term portion	831	3,681
Other financial liabilities - long term portion	(3,562)	(2,190)
Medium long term debt	(443,525)	(395,184)
TOTAL NET LIQUIDITY	(250,257)	(291,905)



ND / E = **0.378** vs. 0.503 AT 31.12.19

CFC = **0,98** vs. 1.38 AT 31.12.19









